Abstract
Improvements in the understanding of the metabolic cross-talk between cancer and its micro-environment are expected to lead to novel therapeutic approaches. Acute myeloid leukemia (AML) cells have increased mitochondria compared to non-malignant CD34+ hematopoietic progenitor cells. Furthermore, contrary to the Warburg hypothesis, (AML) relies on oxidative phosphorylation to generate ATP. Here we report that in human AML, NOX2 generates superoxide which stimulates bone marrow stromal cells (BMSC) to AML blast transfer of mitochondria through AML derived tunnelling nanotubes. Moreover, inhibition of NOX2 was able to prevent mitochondrial transfer, increase AML apoptosis and improve NSG AML mouse survival. Although mitochondrial transfer from BMSC to non-malignant CD34+ cells occurs in response to oxidative stress, NOX2 inhibition had no detectable effect on non-malignant CD34+ cell survival. Taken together we identify tumor-specific dependence on NOX2 driven mitochondrial transfer as a novel therapeutic strategy in AML.
Original language | English |
---|---|
Pages (from-to) | 1649-1660 |
Number of pages | 12 |
Journal | Blood |
Volume | 130 |
Issue number | 14 |
Early online date | 21 Jul 2017 |
DOIs | |
Publication status | Published - 5 Oct 2017 |
Profiles
-
Kristian Bowles
- Norwich Medical School - Dean of Norwich Medical School
- Cancer Studies - Member
Person: Research Group Member, Academic, Teaching & Research
-
Dylan Edwards
- Norwich Medical School - Emeritus Professor
- Norwich Institute for Healthy Aging - Member
- Cancer Studies - Member
Person: Honorary, Research Group Member, Research Centre Member
-
Stephen Robinson
- School of Biological Sciences - Research Leader
- Norwich Institute for Healthy Aging - Member
- Cells and Tissues - Member
Person: Research Group Member, Research Centre Member, Academic, Teaching & Research